Order Article Reprints

Nakabori T, Higashi S, Abe Y, Mukai K, Ikawa T, Konishi K, Maeda N, Nakanishi K, Hasegawa S, Wada H, et al. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology. 2024; 31(3):1543-1555. https://doi.org/10.3390/curroncol31030117

Nakabori, Tasuku, Sena Higashi, Yutaro Abe, Kaori Mukai, Toshiki Ikawa, Koji Konishi, Noboru Maeda, Katsuyuki Nakanishi, Shinichiro Hasegawa, Hiroshi Wada, and et al. 2024. "Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma" Current Oncology 31, no. 3: 1543-1555. https://doi.org/10.3390/curroncol31030117

Nakabori, T., Higashi, S., Abe, Y., Mukai, K., Ikawa, T., Konishi, K., Maeda, N., Nakanishi, K., Hasegawa, S., Wada, H., & Ohkawa, K. (2024). Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology, 31(3), 1543-1555. https://doi.org/10.3390/curroncol31030117